• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Kyowa Hakko Kirin Pharma, Inc. - Product Pipeline Review - Q4 2010 Product Image

Kyowa Hakko Kirin Pharma, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 39 pages
  • GlobalData

Kyowa Hakko Kirin Pharma, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Kyowa Hakko Kirin Pharma, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Kyowa Hakko Kirin Pharma, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Kyowa Hakko Kirin Pharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Kyowa Hakko Kirin Pharma, Inc. Snapshot
Kyowa Hakko Kirin Pharma, Inc. Overview
Key Information
Key Facts
Kyowa Hakko Kirin Pharma, Inc. – Research and Development Overview
Key Therapeutic Areas
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products Glance
Kyowa Hakko Kirin Pharma, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Kyowa Hakko Kirin Pharma, Inc. – Drug Profiles
BIW-8962
Product Description
Mechanism of Action
R&D Progress
KRN125
Product Description
Mechanism of Action
R&D Progress
KRN330
Product Description
Mechanism of Action
R&D Progress
KRN330 + Irinotecan
Product Description
Mechanism of Action
R&D Progress
KW-2450 + Lapatinib + Letrozole
Product Description
Mechanism of Action
R&D Progress
KW-2478 + Bortezomib
Product Description
Mechanism of Action
R&D Progress
KW-2478
Product Description
Mechanism of Action
R&D Progress
KW-3357
Product Description
Mechanism of Action
R&D Progress
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Analysis
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products by Therapeutic Class
Kyowa Hakko Kirin Pharma, Inc. Pipeline Products By Target
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products by Route of Administration
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products by Molecule Type
Kyowa Hakko Kirin Pharma, Inc. - Dormant Projects
Kyowa Hakko Kirin Pharma, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
KW-2449
KW-7158
Kyowa Hakko Kirin Pharma, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Apr 19, 2007: NESP (darbepoetin alfa) Injection Syringe Receives Approval
Apr 19, 2007: NESP (darbepoetin alfa) Injection Syringe Receives Approval
Sep 17, 2002: Kyowa Hakko’s Antiasthmatic Agent, KW-4490, Has Entered Early Phase II Clinical Studies In Europe
May 14, 2002: Kyowa Hakko Begins Clinical Phase II Trials In The U.S. And Europe Of KW-7158, A Treatment For Urinary Incontinence
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Jun 06, 2001: Kyowa Hakko Bigins Phase II Trial Of KW-7158 For Urinary Incontinence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS